KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) Research & Development (2016 - 2025)

Opko Health (OPK) has disclosed Research & Development for 16 consecutive years, with $32.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 7.71% year-over-year to $32.8 million, compared with a TTM value of $124.0 million through Dec 2025, up 17.89%, and an annual FY2025 reading of $124.0 million, up 17.89% over the prior year.
  • Research & Development was $32.8 million for Q4 2025 at Opko Health, up from $30.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $32.8 million in Q4 2025 and bottomed at $17.3 million in Q2 2022.
  • Average Research & Development over 5 years is $23.5 million, with a median of $20.3 million recorded in 2021.
  • The sharpest move saw Research & Development soared 78.05% in 2023, then crashed 32.72% in 2024.
  • Year by year, Research & Development stood at $21.0 million in 2021, then fell by 7.04% to $19.5 million in 2022, then decreased by 0.69% to $19.4 million in 2023, then surged by 56.88% to $30.4 million in 2024, then grew by 7.71% to $32.8 million in 2025.
  • Business Quant data shows Research & Development for OPK at $32.8 million in Q4 2025, $30.1 million in Q3 2025, and $30.3 million in Q2 2025.